PDE5A and pulmonary arterial hypertension: In total, 42 patients (65.6%) had received previous treatment with bosentan, prostanoids, phosphodiesterase-5 (PDE-5) inhibitors, or combinations thereof, before entering the FUTURE 3 core study, and 22 patients (34.4%) were naïve to PAH treatment.